ArticleNeurocritical care2008
Baclofen and gamma-hydroxybutyrate withdrawal.
Article in Neurocritical care, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 55 citations in OpenAlex.
- [Sociodemographic and clinical data among GHB patients-an observational study].Der Nervenarzt · 2026Observational
- Inpatient GHB withdrawal management in an inner-city hospital in Sydney, Australia: a retrospective medical record review.Psychopharmacology · 2023Article
- Article
- Severe illicit gamma-hydroxybutyric acid withdrawal in a pregnant woman: what to do?BMJ case reports · 2019Article
- [Course and complications of GHB detoxification treatment: a 1-year case series].Der Nervenarzt · 2019Article
- Baclofen in gamma-hydroxybutyrate withdrawal: patterns of use and online availability.European journal of clinical pharmacology · 2018Review
- Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.CNS drugs · 2017Review
- Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial.Trials · 2016Article
- ConceptMetab: exploring relationships among metabolite sets to identify links among biomedical concepts.Bioinformatics (Oxford, England) · 2016Article
- Behavioral and Genetic Evidence for GIRK Channels in the CNS: Role in Physiology, Pathophysiology, and Drug Addiction.International review of neurobiology · 2015Review
- Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK.British journal of clinical pharmacology · 2014Article
- Substance of abuse and movement disorders: complex interactions and comorbidities.Current drug abuse reviews · 2012Review
- Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination.Psychopharmacology · 2010Article
- Behavioral analyses of GHB: receptor mechanisms.Pharmacology & therapeutics · 2009Review
- Successful Management of Gamma-hydroxybutyrate (GHB) Withdrawal Using Baclofen as a Standalone Therapy: A Case Report.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionBenzodiazepine treatment of life-threatening gamma-hydroxybutyrate (GHB) withdrawal is frequently unsatisfactory. Animal studies suggest strongly that treatment with GABA(B) agonists, such as baclofen, will be a more effective strategy.
methodsA case report from the medical intensive care unit (ICU) of the university tertiary care hospital.
resultsA 61-year-old woman was admitted to the medical ICU for severe withdrawal symptoms from chronic GHB use. This manifested as delirium, tremor, and seizures despite only small decreases in GHB dose and treatment with benzodiazepines. The addition of baclofen allowed the rapid sequential decreases in the GHB dose without seizure or delirium and resulted in long-term improvement of her tremor.
conclusionsBaclofen, a GABA(B) agonist, may be a useful agent in the treatment of severe GHB withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.